Feasibility and effectiveness of an Asthma/COPD service for primary care

Metting, Esther I.; Riemersma, Roland A.; Kocks, Janwillem H.; Piersma-Wichers, Margriet G.; Sanderman, Robbert; van der Molen, Thys

Published in:
npj Primary Care Respiratory Medicine

DOI:
10.1038/npjpcrm.2014.101

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Feasibility and effectiveness of an Asthma/COPD service for primary care: a cross-sectional baseline description and longitudinal results

Esther I Metting1,2, Roland A Riemersma1,2, Janwillem H Kocks1,2, Margriet G Piersma-Wichers3, Robbert Sanderman4,5 and Thys van der Molen1,2

BACKGROUND: In 2007, an Asthma/chronic obstructive pulmonary disease (COPD) (AC) service was implemented in the North of the Netherlands to support General Practitioners (GPs) by providing advice from pulmonologists on a systematic basis.

AIMS: To evaluate the feasibility and effectiveness of this service on patient-related outcomes.

METHODS: We report baseline data on 11,401 patients and follow-up data from 2,556 patients. GPs can refer all patients with possible obstructive airway disease (OAD) to the service, which is conducted by the local laboratory. Patients are assessed in the laboratory using questionnaires and spirometry. Pulmonologists inspect the data through the internet and send the GP diagnosis and management advice.

RESULTS: A total of 11,401 patients were assessed by the service, covering almost 60% of all adult patients with projected asthma or COPD in the area. In all, 46% (n = 5,268) of the patients were diagnosed with asthma, 18% (n = 2,019) with COPD and 7% (n = 788) with the overlap syndrome. A total of 740 (7%) patients were followed up after 3 months because the GP advised them to change medication. In this group, the proportion of unstable COPD patients (Clinical COPD Questionnaire (CCQ) > 1) decreased from 63% (n = 92) at baseline to 49% (n = 72). The proportion of patients with uncontrolled asthma (Asthma Control Questionnaire (ACQ) > 1.5) decreased from 41% (n = 204) to 23% (n = 115). In all, 938 (8%) patients were followed up after 12 months. From these patients, the proportion of unstable COPD patients (CCQ > 1) decreased from 47% (n = 115) to 44% (n = 107). The proportion of patients with uncontrolled asthma (ACQ > 1.5) decreased from 16% (n = 95) to 14% (n = 85).

CONCLUSION: The AC service assessed a considerable proportion of patients with OAD in the area, improved patients’ outcomes, and is considered to be feasible and effective.

npj Primary Care Respiratory Medicine (2015) 25, 14101; doi:10.1038/npjpcrm.2014.101; published online 8 January 2015

INTRODUCTION

Asthma and chronic obstructive pulmonary disease (COPD) are prevalent chronic diseases in the community.1 In the Netherlands, 60 to 80% of all asthma and COPD patients are treated by their general practitioner (GP), and patients are only referred to the pulmonologist in case of severe uncontrolled asthma or severe COPD.2 Misdiagnosis and underdiagnosis are common,3–5 as asthma and COPD overlap in symptoms, whereas their treatments are different.6 Some patients have both asthma and COPD, the so-called overlap syndrome, which can be described as (partly) reversible but progressive deterioration in lung function, often combined with a history of smoking and previous diagnosis of asthma and/or allergies. These diagnostic problems may lead to suboptimal treatment, whereas early correct treatment can reduce costs, morbidity and mortality, can improve symptoms and enhance patient outcomes.3–5,7

In daily clinical practice, many GPs often lack the knowledge, time and enthusiasm to perform all tasks that are recommended by guidelines. For example, Dutch GPs are obliged to follow 96 guidelines for common diseases, of which only three are concerned with asthma, asthma in children, and COPD.8–10 GPs therefore could benefit from the knowledge and experience of pulmonologists by obtaining advice for each patient with pulmonary symptoms. Cooperation between GPs and other caregivers in integrated care projects for COPD patients has been proven to be effective in improving the quality of life and health status of patients, thus reducing costs and the number of hospitalisations.11,12 Asthma/COPD services in which GPs are supported by pulmonologists in interpreting spirometry results are feasible and might improve diagnostic accuracy.13 GPs and pulmonologists in the North of the Netherlands collaborated and implemented the Asthma/COPD (AC) service in 2007 as a support service for GPs. The aim of this service is to improve the management of asthma and COPD patients in primary care. Although the service was not developed for scientific reasons, data from included patients are available for research. This paper describes the development and feasibility of this service, the patient population and its effect on patient-related outcomes.
MATERIALS AND METHODS

Design and feasibility
Meetings with local physicians were organised, resulting in four starting principles: (1) the service should optimise diagnosis, treatment and management; (2) the GP is in lead; (3) the service should be easily accessible for patients and physicians; (4) allocation of tasks between primary and secondary care have to be defined clearly.14 Yearly meetings are organised to inform physicians about current developments, discuss casuistry and enhance commitment.

The role of the GP. GPs can refer individual patients (≥ 8 years of age) who are suspected to have asthma, COPD, overlap syndrome or present with pulmonary symptoms of unknown origin further referred to as obstructive airway disease (OAD). The GP can also choose to refer all OAD patients in his/her practice on the basis of inhaled medication use and/or courses of prednisolone. When preferred by the GP, referral may also include follow-up assessments by the AC service. Finally, the GP decides what to do with the advice of the pulmonologist and is responsible for the disease management.

Self-reported information by patients. Patients complete the ‘Asthma Control Questionnaire (ACQ),’ the ‘Clinical COPD Questionnaire (CCQ)’ and a medical history questionnaire assessing gender, age, age of onset, family history, symptoms, exacerbations (having used oral corticosteroids or antibiotics for lung problems), allergy and other stimuli-provoking symptoms, medication, occupation and smoking history as part of the regular assessment procedure.

The ACQ is used to measure asthma control and contains six questions (range 0–6), and the total score can be divided into ‘controlled’ (< 0.75), ‘partially controlled’ (0.75–1.50) and ‘uncontrolled’ (≥ 1.50).14 The CCQ is used to measure COPD health status, and it contains 10 questions. The total score (range 0–6) can be distributed between ‘stable’ (< 1), ‘not entirely stable’,12 ‘unstable’12 and ‘very unstable’ (≥ 3). This questionnaire contains three subdomains with four questions about functional status, four questions about symptoms and two questions about mental status.14,15

Assessment by the trained lung function technician. The assessments take place in local laboratories according to a strict protocol. The following measurements are taken:

- Body mass index.
- Evaluation and, if needed, instruction of the inhalation technique according to the Dutch ‘Inhalation Medication Instruction School’ guidelines.
- Spirometry according to international guidelines.16

All data, including the scores on the questionnaires, are inserted in an Electronic Diagnostic Support (EDS) system.

The role of the pulmonologist. Pulmonologists are trained in using the service by following at least two training sessions. In this paper, we included pulmonologists who had assessed ≥ 300 patients to avoid the influence of learning effects. Pulmonologists assess the quality of the spirometry, inspect all outcomes in the Electronic Diagnostic Support (EDS) system. Pulmonologists who had assessed ≥ 300 patients yearly from 79.3% of the GPs in the target area. Approximately 50% of patients were included by practice screening. In all, 60% of all adult asthma and COPD patients in the target area were assessed at least once by the AC service.18,19 Pulmonologists considered the quality of 93.6% of the spirometry graphs to be usable for diagnosis and could diagnose 79.4% of the patients (asthma: 45.8%, COPD: 17.8%, overlap syndrome: 6.9%). See Supplementary 1 for an overview of COPD GOLD A, B, C and D patients at baseline. Baseline diagnosis was compared with follow-up diagnosis, and it did not change during the follow-up in 91.2% (confidence interval: 89.4–92.7%) of baseline asthma patients, in 87.7% (confidence interval: 84.4–90.4%) of baseline COPD patients and in 74.2% (confidence interval: 68.0–79.5%) of baseline overlap syndrome patients. There was variation in diagnostic pattern in adult patients between the different pulmonologists (n = 10, P < 0.000); see Figure 1.

Follow-up visits
Patients frequently changed from GOLD (2013) category, and many GOLD D patients (n = 74) moved to other GOLD categories at follow-up (Follow-up category: GOLD A: 21.6%, B: 36.5%, C: 6.8%, D: 35.1%); see Figure 2.

Patients advised to change medication (Patients followed-up after 3 months, total = 740). Inhalation technique improved significantly (correct at baseline 35.1% to 52.5% after 3 months, n total = 459, P < 0.000). The proportion of well-controlled asthma patients increased from 23.9% (baseline) to 49.5% (3 months, n total = 487, P < 0.000), and the proportion of stable COPD patients increased from 27.4% (baseline) to 48.9% (3 months, n total = 145, P = 0.004). The proportion of GOLD D patients decreased from 12.8% at baseline to 6.7% after 3 months; see Table 3 (n total = 145, P < 0.000).

Patients advised to continue current medication (Patients followed-up after 12 months, n = 938). Inhalation technique did improve significantly (correct baseline 37.4 to 49.9% after 12 months, n = 741, P < 0.000). The proportion of current smokers decreased from 25.2% at baseline to 23.2% after 12 months (n = 984, P = 0.013). The proportion of asthma and COPD patients with ≥ 1
exacerbation last year decreased (asthma: 35.0% at baseline, 25.2% at 12 months, \(P > 0.000\); COPD: 34.8% at baseline, 25.4% at 12 months, \(P = 0.010\)); see Table 4.

**DISCUSSION**

Main findings

In this study, we have evaluated over 11,000 patients referred by 360 different GPs to the Asthma/COPD (AC) service in the North of the Netherlands. With 60% of all asthma and COPD patients in the area participating, the service is well implemented in the target area. We chose to report the follow-up results from patients who were advised to continue with their medication and were scheduled to have a 12-month follow-up. If a change in medication was advised, after 3 months, health status improved in COPD patients and asthma control improved in asthma patients. Asthma and COPD patients who did not need medication change and were referred to the yearly follow-up assessment stabilised in asthma control and in COPD health status. Overlap syndrome patients in this group improved in asthma control and health status. Most (65%) of the GOLD D patients moved to other categories after baseline visit; some of these patients (22%) even improved to GOLD category A. Given these results, we consider the AC service to be a feasible and effective collaboration service for primary and secondary care.

Interpretation of findings in relation to previously published work

According to the Global Initiative for Asthma guidelines, uncontrolled asthma patients would be eligible for referral to...
The prevalence of uncontrolled asthma patients in our population (age ≥ 16 years) is lower (40%) than the prevalence found in the INSPIRE study where 51% of the patients had uncontrolled asthma. Only 13% of our asthma patients were advised to be referred to secondary care (see Table 1), meaning that the pulmonologists did not follow the Global Initiative for Asthma guidelines. However, we do not know whether the GP followed the referral recommendation of the pulmonologist.

The accuracy of the diagnosis in Asthma/COPD support systems is of pivotal importance. Lucas et al. showed previously that a diagnosis based on paper patient data without life contact in an AC service is comparable with diagnoses acquired by a face-to-face consultation. The level of agreement on diagnoses between paper data and face-to-face diagnoses was κ = 0.82, which exceeded the level of inter-doctor agreement from the different assessing pulmonologists (κ = 0.64). We used comparable history questions and spirometry as Lucas et al. used, and we assume that the diagnostic accuracy will be comparable as in the study of Lucas et al.

Diagnoses during follow-up visits in our AC service (see Figure 1) showed that most of the diagnoses were consistent. Although diagnoses are to some extent subjective, the advantage of the system is that the GP can compare his own choices with the diagnoses and advices from the pulmonologist. We believe that this internet-based consultation in the long run might improve skills in the management of OADs.

Van den Bemt et al. presented a service for COPD patients and concluded that it was not clinically effective. However, their population consisted of already-diagnosed COPD patients, and all patients had performed spirometry previously to inclusion, whereas we followed up both previously diagnosed and newly diagnosed patients. We speculate that the room for improvement in our population of a wide range of patients was higher, which might have contributed to the positive effect. Furthermore, internet is used for data exchange, and GPs receive the report from the pulmonologist mostly within 5 working days electronically in their patient information system, which makes the service user friendly. Next to that, the use of Internet and the trained lung function technicians make the service cost-effective. Direct costs were covered by reimbursement for the spirometry in primary care, including the involvement of the pulmonologist.

Generalisability. Our asthma patients differed from COPD patients, whereas the characteristics of overlap syndrome patients fell between asthma and COPD patients. This was also described by Postma et al. who showed that asthma patients are younger, more frequently female and have less frequently a history of smoking. Miravitlles et al. showed the same pattern of patient characteristics in their primary care population, although the proportion of male patients in their overlap syndrome population was much lower than in the AC population (Miravitlles: 26%; AC service: 49%). Characteristics of our asthma patients (≥ 16 years) were comparable with asthmatics from the INSPIRE study (AC service: male, 38%; mean age, 46 ± 17 years; current smokers, 21%. INSPIRE: male 35%; mean age, 45 ± 17 years; current smokers, 21%).

When considering overlap syndrome as a subtype of COPD, the prevalence of overlap syndrome in our COPD population was 28%, which is comparable to the prevalence found by Stallberg et al. (25%) but higher than the prevalence reported by Postma et al.
Lange et al. using CCQ cutoff value of the AC service were distributed according to the GOLD guidelines status and disease control in overlap patients. COPD patients in no validated measurements are available to assess the health the regular assessment in the AC collaboration service. However, the ACQ and the CCQ, because these questionnaires were part of overlap syndrome, 10%). Overlap patients were assessed by using lung function (FEV1/forced vital capacity (FVC) after bronchodilator test (BDT) response.2 In asthma patients with good reversibility than the Danish general population.

In the UPLIFT study, 50% of the COPD patients showed significant impairment in lung function.30 Although COPD is considered to be a nonreversible obstructive lung disease, 11% of our COPD patients had a BDT response, and the average reversibility was 6%. In the UPLIFT study, 50% of the COPD patients showed significant reversibility.31 Obviously, real-life COPD populations differ from selected populations, as confirmed by Kruis et al.25 Bronchodilator response was more prevalent in COPD patients with severe disease.24 The highest proportion of patients with positive BDT response was seen in the overlap syndrome patients (35%), which is consistent with the GOLD and Global Initiative for Asthma recommendations.33

Risk factors. The proportion of smoking COPD and overlap syndrome patients (COPD: 50%, overlap syndrome: 45%) was much higher than in the Dutch population, which is 27%, and also higher than the COPD population presented by Warnier et al.34 (37%). Our definition of smokers might have contributed to the higher proportion, because we considered quitters < 12 months ago as current smokers. The AC service does not provide any

Table 3. Longitudinal differences in lung function, exacerbations, health status and asthma control of patients assessed at baseline and after 3 months (range: 2–4 months, n total = 740)

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Baseline</th>
<th>After 3 months</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asthma (n = 503)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbation last yearb</td>
<td>483</td>
<td>188 (38.9)</td>
<td>92 (18.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Current smoker</td>
<td>497</td>
<td>120 (23.9)</td>
<td>149 (27.9)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td>Sufficient inhalation techniquea</td>
<td>320</td>
<td>120 (23.9)</td>
<td>173 (54.1)</td>
<td></td>
</tr>
<tr>
<td>Well controlled (ACQ &lt; 0.75)</td>
<td>497</td>
<td>119 (23.9)</td>
<td>246 (49.5)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td>Partially controlled (ACQ ≥ 0.75 and &lt; 1.50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncontrolled (ACQ ≥ 1.50)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>455</td>
<td>3.0 (0.9)</td>
<td>2.9 (0.9)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td><strong>COPD (n = 148)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbation</td>
<td>148</td>
<td>60 (40.5)</td>
<td>62 (42.2)</td>
<td>NS</td>
</tr>
<tr>
<td>Current smoker or quit &lt; 12 months ago</td>
<td>147</td>
<td>63 (42.9)</td>
<td>38 (24.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Sufficient inhalation techniquea</td>
<td>79</td>
<td>19 (24.1)</td>
<td>38 (24.1)</td>
<td>NS</td>
</tr>
<tr>
<td>Stable (CCQ &lt; 1)</td>
<td>147</td>
<td>55 (37.4)</td>
<td>75 (51.0)</td>
<td>0.004</td>
</tr>
<tr>
<td>Not entirely stable (CCQ ≥ 1 &amp; &lt; 2)</td>
<td>147</td>
<td>64 (43.5)</td>
<td>48 (32.7)</td>
<td></td>
</tr>
<tr>
<td>Unstable (CCQ ≥ 2 and &lt; 3)</td>
<td>147</td>
<td>19 (12.9)</td>
<td>18 (12.2)</td>
<td></td>
</tr>
<tr>
<td>Very unstable (CCQ ≥ 3)</td>
<td>147</td>
<td>9 (6.1)</td>
<td>6 (4.1)</td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>148</td>
<td>2.1 (0.6)</td>
<td>2.1 (0.6)</td>
<td>NS</td>
</tr>
<tr>
<td><strong>Overlap syndrome (n = 82)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbation</td>
<td>82</td>
<td>41 (50.0)</td>
<td>34 (41.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Current smoker or quit &lt; 12 months ago</td>
<td>82</td>
<td>33 (40.2)</td>
<td>34 (41.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Sufficient inhalation techniquea</td>
<td>58</td>
<td>21 (36.2)</td>
<td>29 (50.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Well controlled (ACQ &lt; 0.75)</td>
<td>82</td>
<td>35 (42.7)</td>
<td>48 (58.5)</td>
<td>NS</td>
</tr>
<tr>
<td>Partially controlled (ACQ ≥ 0.75 and &lt; 1.50)</td>
<td>82</td>
<td>30 (36.6)</td>
<td>19 (23.2)</td>
<td></td>
</tr>
<tr>
<td>Uncontrolled (ACQ ≥ 1.50)</td>
<td>82</td>
<td>17 (20.7)</td>
<td>15 (18.3)</td>
<td></td>
</tr>
<tr>
<td>Stable (CCQ &lt; 1)</td>
<td>31</td>
<td>16 (51.6)</td>
<td>16 (51.6)</td>
<td>0.073</td>
</tr>
<tr>
<td>Stable (CCQ ≥ 1 &amp; &lt; 2)</td>
<td>31</td>
<td>16 (51.6)</td>
<td>16 (51.6)</td>
<td></td>
</tr>
<tr>
<td>Stable (CCQ ≥ 2 and &lt; 3)</td>
<td>31</td>
<td>7 (22.6)</td>
<td>2 (6.5)</td>
<td></td>
</tr>
<tr>
<td>Very unstable (CCQ ≥ 3)</td>
<td>31</td>
<td>0 (0.0)</td>
<td>2 (6.5)</td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>81</td>
<td>2.3 (0.6)</td>
<td>2.3 (0.7)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Patients were referred to the 3-month follow-up assessment if change in medication was advised by the pulmonologist.

Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; NS, not significant.

*P values are two-sided and P values ≥ 0.10 are reported as ‘NS’.

bExacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.

cInhalation technique in patients who use medication at baseline.
mortality data, we assume that 1.8% of the COPD patients have no data on mortality; however, on the basis of national results, and data could not be compared with a control group.36

Established for scientific reasons, resulting in limited follow-up results, and data could not be compared with a control group.36 Therefore, we cannot rule out that results might have been affected by regression to the mean, although regression to the mean, although regression to the mean, although regression to the mean, although regression to the mean.37 See Supplementary 2. We also do not have data on mortality; however, on the basis of national mortality data, we assume that 1.8% of the COPD patients have died in 1 year. Leivseth et al.38 showed that there are no large differences in mortality rates between GOLD A, B, C and D. Therefore, we assume that missed mortality rates hardly affected our COPD follow-up results.

Implications for future research, policy and practice
Relatively simple support for GPs in diagnosing and managing patients with a chronic disease by specialists might result in improved outcomes for these patients in the community. Principles of the AC service might also be suitable in other chronic diseases. The large electronic database from the AC service provides unique opportunities for further research in primary care patients with OADs.

Conclusion
The AC service is feasible, effective and efficient in supporting GPs to diagnose and manage asthma, COPD and overlap syndrome patients. The service stimulates cooperation between primary and secondary care, and delivers support to patients locally which is important in rural areas.

ACKNOWLEDGEMENTS
We thank the Northern General Practitioners Laboratory Groningen (LabNoord currently Certe Laboratories) for giving us the opportunity to realise the AC service.

Table 4. Longitudinal differences in lung function, exacerbations, health status and asthma control of patients referred by their GP to single or yearly follow-up assessment after 12 months (range 10–14 months, n total = 991). Patients in this table were not assessed after 3 months

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>n</th>
<th>Baseline</th>
<th>After 12 months</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asthma (n = 598)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbationa</td>
<td>572</td>
<td>200 (35.0)</td>
<td>144 (25.2)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td>Current smokers or quit &lt; 12 months ago</td>
<td>595</td>
<td>88 (14.8)</td>
<td>81 (13.6)</td>
<td>NS</td>
</tr>
<tr>
<td>Sufficient inhalation techniquec</td>
<td>471</td>
<td>185 (39.3)</td>
<td>251 (53.3)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td>Well controlled (ACQ &lt; 0.75)</td>
<td>291</td>
<td>377 (63.8)</td>
<td>383 (64.8)</td>
<td>NS</td>
</tr>
<tr>
<td>Partially controlled (ACQ ≥ 0.75 and &lt; 1.50)</td>
<td>119 (20.1)</td>
<td>123 (20.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncontrolled (ACQ ≥ 1.50)</td>
<td>95 (16.1)</td>
<td>85 (14.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>596</td>
<td>3.1 (0.9)</td>
<td>3.0 (0.9)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td><strong>COPD (n = 245)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbationb</td>
<td>244</td>
<td>85 (34.8)</td>
<td>62 (25.4)</td>
<td>0.010</td>
</tr>
<tr>
<td>Current smokers or quit &lt; 12 months ago</td>
<td>243</td>
<td>109 (44.9)</td>
<td>99 (40.7)</td>
<td>0.017</td>
</tr>
<tr>
<td>Sufficient inhalation techniquec</td>
<td>177</td>
<td>59 (33.3)</td>
<td>78 (44.1)</td>
<td>0.034</td>
</tr>
<tr>
<td>Stable (CCQ &lt; 1)</td>
<td>243</td>
<td>128 (52.7)</td>
<td>136 (56.0)</td>
<td>NS</td>
</tr>
<tr>
<td>Not entirely stable (CCQ ≥ 1 and &lt; 2)</td>
<td>79 (32.5)</td>
<td>74 (30.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unstable (CCQ ≥ 2 &amp; &lt; 3)</td>
<td>23 (9.5)</td>
<td>24 (9.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very unstable (CCQ ≥ 3)</td>
<td>13 (5.3)</td>
<td>9 (3.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>244</td>
<td>2.2 (0.7)</td>
<td>2.1 (0.6)</td>
<td>&lt; 0.000</td>
</tr>
<tr>
<td><strong>Overlap syndrome (n = 88)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 1 exacerbationb</td>
<td>88</td>
<td>34 (38.6)</td>
<td>25 (28.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Current smokers or quit &lt; 12 months ago</td>
<td>88</td>
<td>38 (43.2)</td>
<td>34 (38.6)</td>
<td>0.094</td>
</tr>
<tr>
<td>Sufficient inhalation techniquec</td>
<td>66</td>
<td>24 (36.4)</td>
<td>28 (42.4)</td>
<td>NS</td>
</tr>
<tr>
<td>Well controlled (ACQ &lt; 0.75)</td>
<td>87</td>
<td>37 (42.5)</td>
<td>48 (55.2)</td>
<td>0.032</td>
</tr>
<tr>
<td>Partially controlled (ACQ ≥ 0.75 and &lt; 1.50)</td>
<td>25 (28.7)</td>
<td>21 (24.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncontrolled (ACQ ≥ 1.50)</td>
<td>25 (28.7)</td>
<td>18 (20.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stable (CCQ &lt; 1)</td>
<td>65</td>
<td>24 (36.9)</td>
<td>30 (46.2)</td>
<td>0.027</td>
</tr>
<tr>
<td>Not entirely stable (CCQ ≥ 1 &amp; &lt; 2)</td>
<td>27 (41.5)</td>
<td>26 (40.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unstable (CCQ ≥ 2 &amp; &lt; 3)</td>
<td>7 (10.8)</td>
<td>7 (10.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Very unstable (CCQ ≥ 3)</td>
<td>7 (10.8)</td>
<td>2 (3.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>FEV1 pre (L)</td>
<td>88</td>
<td>2.3 (0.7)</td>
<td>2.2 (0.7)</td>
<td>&lt; 0.000</td>
</tr>
</tbody>
</table>

Abbreviations: ACQ, Asthma Control Questionnaire; CCQ, Clinical COPD Questionnaire; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in one second; GP, general practitioner; NS, not significant.

* P values are two-sided and P values ≥ 0.10 are reported as ‘ns’.

*aExacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.

*bExacerbations are defined as having used oral corticosteroids or antibiotics for lung problems last year.

*cInhalation technique in patients who use medication at baseline.

Strengths and limitations of this study
The strength of this study is the large population of primary care OAD patients in real life and the strict protocol used to assess these patients. A limitation is that the AC service was not established for scientific reasons, resulting in limited follow-up results, and data could not be compared with a control group.26 Therefore, we cannot rule out that results might have been affected by regression to the mean, although regression to the mean (measured by 1 – ρ) is small,37 see Supplementary 2. We also do not have data on mortality; however, on the basis of national mortality data, we assume that 1.8% of the COPD patients have died in 1 year. Leivseth et al.38 showed that there are no large differences in mortality rates between GOLD A, B, C and D. Therefore, we assume that missed mortality rates hardly affected our COPD follow-up results.

Like in other studies,35 many patients (64%) showed an insufficient inhalation technique. Although the inhalation technique improved after 3 (50%) and 12 months (47%) of follow-up after our standard instruction as recommended in the Dutch guidelines, it is debatable whether this instruction is sufficiently effective. Further research on effective instruction seems to be needed.

References
CONTRIBUTIONS
All authors have contributed to writing and revising the manuscript.

COMPETING INTERESTS
RAR is a member of the advisory board of Certe Laboratories. MGP-W is the director of Certe Laboratories. TvDM is a member of the board of trustees of Certe Laboratories. JWHK is an Associate editor of npj Primary Care Respiratory Medicine, but was not involved in the editorial review of, nor the decision to publish, this article. The other authors declare no conflict of interest.

FUNDING
Funding was received from the University Medical Center Groningen.

REFERENCES
2 Global Initiative for Asthma. Pocket guide for asthma management and prevention, 2012; Available at http://www.ginasthma.org/.
11 Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD, 2013; Available at http://www.goldcopd.org/

Supplemental information accompanies the paper on the npj Primary Care Respiratory Medicine website (http://www.nature.com/npjpcrm)